The world desperately needs an effective TB vaccine to reduce the illness and death still being caused by the centuries’ old bacterium. Chris Bateman visited a study site in Paarl where a promising experimental TB vaccine is now being tested as part of a large multi-country clinical trial.
Both TB treatment and TB preventive therapy involve taking lots of pills, usually for several months. Researchers are working on new long-acting formulations that might, for example, reduce an entire course of TB preventive therapy to a single injection. Catherine Tomlinson reports.
The TB Sustainable Development Goals of reducing incidence and deaths from TB are achievable, if we all work together. We must double down on this ambition and be even bolder in our investments, write Yogan Pillay and Gaurang Tanna.
Medical researchers in South Africa are in limbo as they wait to hear whether over R800 million in research grants from the United States National Institutes of Health will be terminated. South Africa’s top universities, which receive the bulk of the funding, will be particularly hard hit if the cuts materialise. Catherine Tomlinson reports.
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Elri Voigt reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the Conference on Retroviruses and Opportunistic Infections.
While the 2025 national budget boosts health spending, researchers from the South African Medical Research Council stress the need for strong accountability measures. They also raise concerns about rising VAT and omissions related to US funding cuts and climate change.
Elzette Rousseau from the Desmond Tutu HIV Foundation told attendees at the top HIV conference in The United States about a project taking HIV prevention services to schools in Cape Town. Biénne Huisman visited one of the sites to find out how it works.
After the US slashed global aid, the South African government stated that only 17% of its HIV spending relied on US funding. But some experts argue that US health initiatives had more bang for buck than the government’s programmes. Jesse Copelyn looks past the 17% figure, and considers how the health system is being affected by the loss of US money.
A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in funding from the United States government. As a result, several promising vaccine candidates might not be tested in clinical trials. Catherine Tomlinson reports.
Amid major disruptions caused by aid cuts from the United States government, the health department aims to enrol a record number – an additional 1.1 million – of people living with HIV on life-saving antiretroviral medicine this year. Experts tell Spotlight it can’t be business as usual if this ambitious programme is to have a chance of succeeding. Ufrieda Ho reports.
Just over a month after US President Donald Trump implemented a 90-day freeze of all foreign assistance, the future looks very uncertain for tuberculosis research. Among others, a large TB research programme that was worth up to $200 million was axed last week. Elri Voigt reports.
South Africa faces its worst health crisis in 20 years. Worse than COVID, and one that will overshadow diabetes as a major killer, while pouring petrol on a dwindling TB fire. But it is preventable, argues Professor Francois Venter if our government steps up urgently.
